PAL Equatorial Palm Oil Plc

RNS No 2295e
PALL CORPORATION
28th August 1997
 
Pall Corporation Signs Licensing Agreement with Quadrant Healthcare plc 
 
           EAST HILLS, N.Y.--(BW HealthWire)--Aug. 28, 1997--Pall 
Corporation (NYSE: PLL) today announced it has signed an exclusive, 
worldwide licensing agreement with Quadrant Healthcare plc, a 
biopharmaceutical company based in Cambridge, England.  Quadrant owns
proprietary technology that may enable platelets to be dried, stored 
longer than fresh platelets and reconstituted for transfusion.  Use 
of this technology will significantly improve the quality and 
availability of this critical blood product.  The new technology is 
expected to be available for sale within 3-5 years, with a worldwide 
market potential estimated at $150 million.  Pursuant to the terms of
the agreement, Quadrant and Pall will work jointly to prove 
feasibility.  Pall may exercise its rights to commercialize this 
technology.  

    Eric Krasnoff, Chairman and CEO of Pall Corporation said, "We are
excited about working with Quadrant and the prospects for this 
breakthrough technology to improve the safety of our blood supply.  
Currently, platelets can only be stored at room temperature and for 
no longer than 5 days.  Red cells, by comparison, are stored in a 
refrigerator for up to 42 days.  The ability to extend platelet 
viability for considerably longer periods of time will improve the 
availability of this critical blood product.  It should also 
eliminate the problem of post-collection bacterial growth.  Recent 
best estimates state that approximately one in 2,000 platelet units 
have bacterial contamination.  There are over 8 million units of 
platelet concentrate transfused annually in the U.S. alone."  

    Iain Ross, Quadrant Healthcare's Chief Executive commented, "Pall
is an ideal partner for Quadrant.  It is an international leader in 
the field of blood filtration and separations and is therefore 
perfectly placed to develop and commercialize our technology.  
Scientists from both companies will collaborate to further develop 
the technology."  

    Pall Corporation, with annual sales over $1 billion, is based in 
East Hills, New York.  The Company has the broadest based filtration 
and separations capabilities in the world.  Since 1946, Pall 
Corporation has demonstrated technological leadership and innovative 
solutions to complex fluid clarification and purification problems in
each of its three major markets, Health Care, Aeropower and Fluid 
Processing.      The Company employs 8,300 people at offices 
throughout the world with manufacturing facilities in the United 
States, Puerto Rico, England, Ireland, Japan, China and India.  The 
Company's shares are listed on the New York Stock Exchange (PLL) and 
the London Stock Exchange (0668260).  

    Quadrant was established in 1988 to commercialize the trehalose 
stabilization technology.  Today, under a management team experienced
in biopharmaceutical R&D, Quadrant aims to create maximum shareholder
value through the application of specific aspects of its core drug 
delivery technology to enhance the development of its own product 
pipeline and by entering into collaborative agreements with large 
international healthcare groups as appropriate.  

    This release contains "forward-looking statements" as defined in
the Private Securities Litigation Reform Act of 1995.  As indicated 
above, achievement of the results which Pall and Quadrant are working
toward depends on various factors, including the successful 
completion of development of the technology and proof of feasibility 
which are conditions to obtaining regulatory approval and market 
acceptance.  
     
           CONTACT:  Pall Corp.
                     Patricia Iannucci, 516/484-3600

END

Equatorial Palm Oil (LSE:PAL)
Historical Stock Chart
From Jun 2024 to Jul 2024

Equatorial Palm Oil (LSE:PAL)
Historical Stock Chart
From Jul 2023 to Jul 2024